Executive Summary
This overnight filing cycle reveals a bifurcated market environment where insider conviction is sharply divided. On the bullish side, multiple **Vera Bradley** executives and directors have made significant open-market purchases totaling over $200K, signaling deep management conviction in a turnaround at deeply depressed prices. **PayPal's** CFO also added $255K in stock, a strong vote of confidence.
Conversely, notable bearish signals emerge from **Natera** and **Talkspace**, where insiders have sold large blocks—Natera's Executive Chairman alone sold $2.58M under a 10b5-1 plan. The most high-impact corporate actions are the **Organon-Sun Pharma $7B+ acquisition** (definitive proxy filed, vote July 23) and a **Holcim tender offer for Cementos Pacasmayo** signaling a full buyout. A critical risk flag is raised by **JBDI Holdings**, which faces a Nasdaq delisting deadline on July 6, 2026, with a reverse split its last-ditch compliance effort. On the capital allocation front, **NeoGenomics** priced a convertible note offering (likely ~$300M+ range), while **Toyota** disclosed strong operating income performance but a low 8% ROE benchmark, suggesting room for improved capital efficiency. Several biotech entities—**Alterity Therapeutics** and **Theravance Biopharma**—filed routine director grants, providing no material signals. Overall, the digest points to a market theme of selective insider conviction amidst M&A and regulatory overhangs.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4 · Schedule 13D · 20-F · 425 · 8-K · DEFM14A
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from June 10, 2026.
Investment Signals (12)
- Vera Bradley ↓ (BULLISH)▲
CEO bought $112K, Director bought $93K—both at ~$3.70-3.87—multiple insiders doubling down near 52-week lows, signaling belief in fundamental turnaround. No forward guidance yet.
- PayPal ↓ (BULLISH)▲
CFO Miller bought $255K of stock at $41.53, while President Keller received 146,778 PSUs—combined insider confidence in execution amid fintech sector pressure.
- Enovis ↓ (BULLISH)▲
CAO Oliver bought $21K at $20.92, a positive insider sign near recent lows for this med-tech firm.
- Natera ↓ (BEARISH)▲
Executive Chairman Rabinowitz sold $2.58M of stock under a 10b5-1 plan at ~$210-212, a very large insider liquidation despite the company's growth story.
- Talkspace ↓ (BEARISH)▲
CEO had $522K in stock withheld for taxes (vesting), but CLO sold $283K on the open market—net insider selling pressure at elevated post-pandemic levels.
- Shoals Technologies ↓ (BEARISH)▲
CLO sold $104K, plus had $129K withheld for taxes—combined insider cash-out while solar/solar infrastructure stocks remain under pressure.
- Garrett Motion ↓ (BEARISH)▲
SVP Rodrigues sold $356K under a 10b5-1 plan—significant disposal by a top turbo tech executive.
- Vroom ↓ (BULLISH)▲
Director Mudrick Capital bought $113K in stock and $156 in warrants—activist insider adding to a high-risk used-auto play with significant leverage.
- Navios Maritime Partners ↓ (BULLISH)▲
CEO Frangou bought $249K across three trades at $73.63-74.73—consistent buying by the chairman/CEO in a shipping company with high cash generation.
- Spire Global ↓ (BULLISH)▲
CEO Condor exercised 21,121 options at $7.04-7.84 while having 14,423 shares withheld for taxes—net position increase signals confidence in space-based data growth.
-
Director gifted 30,000 shares—non-sale but notable large transfer; could signal estate planning ahead of expected lockup expiry or future sale. [NEUTRAL/NEGATIVE]
- Wing Yip Food Holdings ↓ (BULLISH)▲
Regained Nasdaq compliance after ADS closed above $1 for 10 consecutive days—removes delisting overhang for this Chinese food company.
Risk Flags (9)
- JBDI Holdings / Nasdaq Delisting↓ [HIGH RISK]▼
Stock received deficiency notice; 1-for-2 reverse split effective June 25, 2026—if compliance not met by July 6, shares face delisting. HIGH RISK.
- Organon & Co. / M&A Execution Risk↓ [HIGH RISK]▼
Acquisition by Sun Pharma requires majority of outstanding shares (not just votes cast) to approve; abstentions count as 'no' votes. With institutional ownership at ~70%, any activist opposition could derail the $7B+ deal.
- NeoGenomics / Convertible Note Dilution↓ [MEDIUM RISK]▼
Announced convertible senior note pricing (due 2032)—typical structure includes capped call and potential dilution of ~10-15% if conversion occurs. No terms disclosed yet, but leverage increases.
- Talkspace / Multiple Insiders Vesting & Selling↓ [MEDIUM RISK]▼
Four insiders (CEO, CFO, CLO, CMO) had significant shares withheld for taxes; CLO additionally sold $283K. Heavy insider liquidity events near $5.20 create overhead supply risk.
- Toyota Motor / Low ROE Benchmark↓ [MEDIUM RISK]▼
Despite strong STI performance (134% of ¥2.5T target), ROE evaluation benchmark is only 8%—well below global auto peers (15-20%). Suggests capital efficiency issues persist despite strategic stake sales.
- NEXTNAV / General Counsel Insider Sale↓ [LOW RISK]▼
GC sold $43K under a 10b5-1 plan—minor amount but part of ongoing insider selling pattern in this GPS technology firm.
- Comtech Telecommunications / Complex Capital Structure↓ [MEDIUM RISK]▼
White Hat Capital's 9.99% blocker provision and Series B-3 convertible preferred shares create opaque overhang; subordinated credit agreement amendments suggest financial covenant pressure.
-
Despite 97-99% approval on AGM items, only 437M of 642M shares voted on Item 1—~32% abstention. Unusually low turnout for a state-controlled utility could signal governance concerns.
- Magnum Ice Cream / Option Overhang↓ [LOW RISK]▼
Granted 2.4M+ options to 6 executives on June 16, 2026 (CFO alone received 1.33M options worth €20.4M). Massive option grants dilute existing shareholders if/upon exercise.
Opportunities (9)
- Vera Bradley / Turnaround Insider Buying↓ (OPPORTUNITY)◆
CEO and Director bought $205K combined at $3.73-3.87. Current market cap ~$110M with zero debt and strong brand equity—insider buying at these levels signals potential 50-100% upside if restructuring succeeds.
- PayPal / CFO's $255K Vote of Confidence↓ (OPPORTUNITY)◆
CFO Miller's open-market purchase at $41.53, combined with PSU grants to President Keller, suggests management sees value. At ~15x forward earnings, PayPal trades at a discount to fintech peers (18-25x).
- ◆
CEO Frangou bought $249K at $73-75. NMM yields ~12% dividend, trades at 4x EBITDA. Insider buying at these levels suggests deep value in shipping cycles.
- Holcim Tender Offer / Cementos Pacasmayo (OPPORTUNITY)◆
Holcim (50.01% owner) determined to proceed with public tender offer for all remaining shares. Potential full buyout at premium to current price—compelling merger arbitrage opportunity with limited downside.
- Wing Yip Food Holdings / Nasdaq Compliance Catalyst↓ (OPPORTUNITY)◆
Regained compliance after ADS closed above $1 for 10 days—delisting risk removed. Chinese food company with KOSDAQ dual listing and century-old brand. Recovery play from distressed levels.
- Vroom / Activist Insider Adding↓ (OPPORTUNITY)◆
Mudrick Capital Management bought $113K of stock and warrants at $7.22. If Vroom executes its used-car platform turnaround, Mudrick's involvement signals potential for operational improvement and value unlock.
- ◆
Four directors each received 6,009 shares and 13,398 options—unusual large uniform grants suggest confidence in pipeline progress, particularly Yupelri and ampreloxetine. At ~$2.50/share, TBPH is near cash value with royalty upside.
- Aegon / Redomiciliation & Leadership Catalyst↓ (OPPORTUNITY)◆
Moving HQ to NYC from Bermuda, appointing new President/COO (Will Fuller). Redomiciliation to US could unlock index inclusion and institutional ownership increase. Valuation at 0.5x book value—potential rerating catalyst.
- Spire Global / CEO Exercise of Deep ITM Options↓ (OPPORTUNITY)◆
CEO exercised 21,121 options at $7.04-7.84 while stock trades at $18.23—150%+ unrealized gain. Shows management confidence in space services growth trajectory.
Sector Themes (6)
- Insider Buying vs Selling Dichotomy (SECTOR THEME)◆
Among 50 filings, open-market buying (Vera Bradley, PayPal, Enovis, Vroom, Navios) is concentrated in small/mid-cap value and distressed names, while selling appears in growth tech (Natera $2.58M sold, Talkspace $283K sold). Pattern suggests insider rotation from high-multiple growth to deep value.
- Nasdaq Compliance Wave (SECTOR THEME)◆
Three companies in this cycle (JBDI, Wing Yip, potentially POMDOCTOR) addressed bid price compliance. Reverse splits (JBDI: 1-for-2; POMDOCTOR: 1-for-18 ADR ratio) are mechanical but signal underlying fundamental weakness in small-cap listings.
- M&A and Corporate Control Activity (SECTOR THEME)◆
Multiple filings involve control changes—Organon/Sun Pharma (vote July 23), Holcim/Cementos Pacasmayo (tender offer), Aegon redomiciliation. Suggest increased private equity and strategic buyer interest in mid/large caps with stable cash flows.
- Convertible Debt and Dilution Financing (SECTOR THEME)◆
NeoGenomics priced convertible notes (due 2032), joining a trend of biotech/med-tech firms using convertibles to fund operations. Avoids equity dilution at low prices but adds balance sheet leverage.
- Biotech Director Grants Without Market Signal (SECTOR THEME)◆
Multiple Theravance directors received uniform equity awards (6,009 shares + 13,398 options), and Alterity reported similar routine grants. These are typical annual compensation, not trading signals—but the consistency suggests stabilization in development-stage biotech.
- Japanese Firms Improving Governance Transparency (SECTOR THEME)◆
Toyota's detailed 20-F filing with board independence analysis, strategic stake disclosures, and executive compensation metrics shows continued governance improvement in Japan. But low 8% ROE target signals room for improvement.
Watch List (8)
- 👁
Stockholders vote on Sun Pharma acquisition on July 23, 2026. Record date June 15. Watch for ISS/Glass Lewis recommendations and any activist opposition.
- 👁
Reverse split effective June 25; compliance deadline July 6. Failure to maintain $1 bid post-split will trigger delisting proceedings. Monitor daily closing prices.
- Holcim / Cementos Pacasmayo Tender Offer (WATCH)👁
Public tender offer for remaining 49.99% of CPAC shares. Watch offer price, timeline, and Peruvian regulatory approvals. Could be a quickly profitable arbitrage.
- 👁
Pricing announcement expected soon. Watch interest rate, conversion premium, and capped call structure. Will set the cost of capital for this med-tech firm.
-
Subordinated credit agreement amended to suspend certain covenants until July 31, 2027. Watch Q3/Q4 results for revenue stabilization and any further debt renegotiations.
- 👁
HQ move to NYC, President/COO appointment effective Jan 1, 2027. Watch for regulatory approvals and potential NYSE listing change. Could re-rate if US-listed peers trade at premium.
- 👁
After large CFO and CEO tax withholdings, watch for any additional Form 4 filings. If selling continues, shares could test $5 support.
-
$2.58M sold under a trading plan. Watch for plan termination date and any additional scheduled sales, as continued selling could pressure the stock despite strong revenue growth.
Filing Analyses
(50)
16-06-2026
Director House Rebecca W exercised/converted 3,940 Common Stock. House Rebecca W holds 6,191 shares after the transaction.
- · Director House Rebecca W exercised/converted 3,940 Common Stock
- · Director House Rebecca W exercised/converted 3,940 Restricted Stock Units
16-06-2026
Chief Executive Officer Bickley Ian bought 28,901 Common Shares at $3.87 (~$112K). Bickley Ian holds 135,623 shares after the transaction.
- · Chief Executive Officer Bickley Ian bought 28,901 Common Shares at $3.87 (~$112K)
16-06-2026
Chief Financial Officer Layding Martin had withheld for taxes 29,376 Common Stock at $3.46 (~$102K). Layding Martin holds 459,570 shares after the transaction.
- · Chief Financial Officer Layding Martin had withheld for taxes 13,989 Common Stock at $3.46 (~$48.4K)
- · Chief Financial Officer Layding Martin had withheld for taxes 29,376 Common Stock at $3.46 (~$102K)
16-06-2026
Director Meslow Andrew bought 24,926 Common Shares at $3.73 (~$93K). Meslow Andrew holds 650,000 shares after the transaction.
- · Director Meslow Andrew bought 24,926 Common Shares at $3.73 (~$93K)
16-06-2026
Chief Administrative Officer Engert Oliver bought 1,000 Common stock, par value $0.001 at $20.92 (~$20.9K). Engert Oliver holds 53,640 shares after the transaction.
- · Chief Administrative Officer Engert Oliver bought 1,000 Common stock, par value $0.001 at $20.92 (~$20.9K)
16-06-2026
SVP, GM GBEs Turbo Tech Rodrigues Mark Albert sold 10,516 Common Stock at $33.82 (~$356K). Rodrigues Mark Albert holds 83,178 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · SVP, GM GBEs Turbo Tech Rodrigues Mark Albert sold 10,516 Common Stock at $33.82 (~$356K)
16-06-2026
Chief Administrative Officer Engert Oliver was awarded 1,000 Common stock, par value $0.001 at $20.99 (~$21K). This amends a previously filed Form 4. Engert Oliver holds 52,640 shares after the transaction.
- · Chief Administrative Officer Engert Oliver was awarded 1,000 Common stock, par value $0.001 at $20.99 (~$21K)
16-06-2026
Pres., Checkout Sol. & PayPal Keller Frank was awarded 146,778 Performance Stock Units 1.
- · Pres., Checkout Sol. & PayPal Keller Frank was awarded 146,778 Performance Stock Units 1
16-06-2026
White Hat Capital Partners LP and affiliated entities filed an amended Schedule 13D on June 16, 2026, disclosing aggregate beneficial ownership of 5,056,520 shares of Comtech Telecommunications Corp. (CMTL) common stock, representing 9.99% of shares outstanding, subject to a blocker provision limiting conversion of Series B-3 Convertible Preferred Stock. The filing also details an amendment to the subordinated credit agreement in connection with a Securities Purchase Agreement with Wavestream Corporation (an affiliate of Gilat Satellite Networks), which suspends certain financial covenants until the four-quarter period ending July 31, 2027, and modifies make-whole premium calculations on $65 million of subordinated term loans.
- · The filing is Amendment No. 5 to the original Schedule 13D filed January 24, 2024.
- · The blocker provision limits conversion of Series B-3 Convertible Preferred Stock to prevent exceeding 9.99% beneficial ownership.
- · Voting power of shares issuable upon conversion of Series B-3 Preferred Stock is subject to restrictions in a Voting Agreement.
- · Lender Warrants vest on October 17, 2026, but are forfeited if Closing Date Term Loans are repaid in full before that date.
- · The make-whole premium on $65M subordinated term loans is 50% before April 1, 2027, and 75% after that date, plus accrued interest at 16% per annum.
- · Financial covenant testing (fixed charge coverage ratio, net leverage ratio, minimum EBITDA) is suspended until the four-quarter period ending July 31, 2027.
16-06-2026
Chief Executive Officer DEGIGLIO MICHAEL A exercised/converted 33,334 Common Shares at $1.08 (~$36K). DEGIGLIO MICHAEL A holds 9,655,775 shares after the transaction.
- · Chief Executive Officer DEGIGLIO MICHAEL A exercised/converted 33,334 Common Shares at $1.08 (~$36K)
- · Chief Executive Officer DEGIGLIO MICHAEL A exercised/converted 33,334 Options
16-06-2026
Chief Executive Officer Donnez Karim had withheld for taxes 43,475 Common Stock at $1.19 (~$51.7K). Donnez Karim holds 1,574,633 shares after the transaction.
- · Chief Executive Officer Donnez Karim had withheld for taxes 43,475 Common Stock at $1.19 (~$51.7K)
16-06-2026
Head of Global Sales & Mktg. Bekefy Jon had withheld for taxes 662 Common Stock at $1.19 (~$788). Bekefy Jon holds 192,108 shares after the transaction.
- · Head of Global Sales & Mktg. Bekefy Jon had withheld for taxes 662 Common Stock at $1.19 (~$788)
16-06-2026
General Counsel & Board Sec. Gerrard Allen had withheld for taxes 848 Common Stock at $1.19 (~$1.01K). Gerrard Allen holds 182,212 shares after the transaction.
- · General Counsel & Board Sec. Gerrard Allen had withheld for taxes 848 Common Stock at $1.19 (~$1.01K)
16-06-2026
Chief Fin & Op Officer Miller Jamie S bought 6,129 Common Stock at $41.53 (~$255K). 6 transactions reported in total. Miller Jamie S holds 76,904 shares after the transaction.
- · Chief Fin & Op Officer Miller Jamie S exercised/converted 9,094 Common Stock
- · Chief Fin & Op Officer Miller Jamie S exercised/converted 2,910 Common Stock
- · Chief Fin & Op Officer Miller Jamie S bought 6,129 Common Stock at $41.53 (~$255K)
- · Chief Fin & Op Officer Miller Jamie S was awarded 146,778 Performance Stock Units 1
- · Chief Fin & Op Officer Miller Jamie S exercised/converted 9,094 Restricted Stock Units -1
- · Chief Fin & Op Officer Miller Jamie S exercised/converted 2,910 Restricted Stock Units -2
16-06-2026
Director Mudrick Capital Management, L.P. bought 15,595 Common Stock at $7.22 (~$113K). Mudrick Capital Management, L.P. holds 3,982,846 shares after the transaction.
- · Director Mudrick Capital Management, L.P. bought 15,595 Common Stock at $7.22 (~$113K)
- · Director Mudrick Capital Management, L.P. bought 15,595 Warrants at $0.01 (~$156)
16-06-2026
Director Green Frederec was awarded 2,476 Common Units at $52.49 (~$130K). This amends a previously filed Form 4. Green Frederec holds 83,514 shares after the transaction.
- · Director Green Frederec was awarded 2,476 Common Units at $52.49 (~$130K)
16-06-2026
Director Mudrick Capital Management, L.P. bought 15,595 Common Stock at $7.22 (~$113K). Mudrick Capital Management, L.P. holds 3,982,846 shares after the transaction.
- · Director Mudrick Capital Management, L.P. bought 15,595 Common Stock at $7.22 (~$113K)
- · Director Mudrick Capital Management, L.P. bought 15,595 Warrants at $0.01 (~$156)
16-06-2026
Chief Legal Officer King Bobbie Lee Jr sold 10,000 Class A Common Stock at $10.41 (~$104K). 4 transactions reported in total. King Bobbie Lee Jr holds 97,918 shares after the transaction.
- · Chief Legal Officer King Bobbie Lee Jr had withheld for taxes 6,377 Class A Common Stock at $10.30 (~$65.7K)
- · Chief Legal Officer King Bobbie Lee Jr had withheld for taxes 6,377 Class A Common Stock at $9.96 (~$63.5K)
- · Chief Legal Officer King Bobbie Lee Jr sold 10,000 Class A Common Stock at $10.41 (~$104K)
- · Chief Legal Officer King Bobbie Lee Jr gifted 1,000 Class A Common Stock
16-06-2026
SVP & CAO Forusz Jillian had withheld for taxes 80 Common Stock at $206.36 (~$16.5K). 6 transactions reported in total. Forusz Jillian holds 3,824.156 shares after the transaction.
- · SVP & CAO Forusz Jillian exercised/converted 234 Common Stock
- · SVP & CAO Forusz Jillian had withheld for taxes 80 Common Stock at $206.36 (~$16.5K)
- · SVP & CAO Forusz Jillian exercised/converted 227 Common Stock
- · SVP & CAO Forusz Jillian had withheld for taxes 78 Common Stock at $206.36 (~$16.1K)
- · SVP & CAO Forusz Jillian exercised/converted 234 Restricted Stock Units
- · SVP & CAO Forusz Jillian exercised/converted 227 Restricted Stock Units
16-06-2026
Director GRAY SUSANNAH was awarded 6,009 Ordinary Shares. GRAY SUSANNAH holds 48,146 shares after the transaction.
- · Director GRAY SUSANNAH was awarded 6,009 Ordinary Shares
- · Director GRAY SUSANNAH was awarded 13,398 Share Option (Right to Buy)
16-06-2026
PRESIDENT, CEO, EXEC CHAIRMAN ROSENSWEIG DANIEL had withheld for taxes 6,337 Common Stock at $1.11 (~$7.03K). This amends a previously filed Form 4. ROSENSWEIG DANIEL holds 7,633,778 shares after the transaction.
- · PRESIDENT, CEO, EXEC CHAIRMAN ROSENSWEIG DANIEL had withheld for taxes 1,956 Common Stock at $1.11 (~$2.17K)
- · PRESIDENT, CEO, EXEC CHAIRMAN ROSENSWEIG DANIEL had withheld for taxes 6,337 Common Stock at $1.11 (~$7.03K)
16-06-2026
Director MITCHELL DEAN J was awarded 6,009 Ordinary Shares. MITCHELL DEAN J holds 97,213 shares after the transaction.
- · Director MITCHELL DEAN J was awarded 6,009 Ordinary Shares
- · Director MITCHELL DEAN J was awarded 13,398 Share Option (Right to Buy)
16-06-2026
Director O'Connor Donal was awarded 6,009 Ordinary Shares. O'Connor Donal holds 80,213 shares after the transaction.
- · Director O'Connor Donal was awarded 6,009 Ordinary Shares
- · Director O'Connor Donal was awarded 13,398 Share Option (Right to Buy)
16-06-2026
Director PAKIANATHAN DEEPIKA was awarded 6,009 Ordinary Shares. PAKIANATHAN DEEPIKA holds 64,074 shares after the transaction.
- · Director PAKIANATHAN DEEPIKA was awarded 6,009 Ordinary Shares
- · Director PAKIANATHAN DEEPIKA was awarded 13,398 Share Option (Right to Buy)
16-06-2026
EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 12,142 Common Stock at $212.27 (~$2.58M). 21 transactions reported in total. Rabinowitz Matthew holds 2,277,843 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 2,536 Common Stock at $209.50 (~$531K)
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 3,267 Common Stock at $210.30 (~$687K)
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 2,957 Common Stock at $211.61 (~$626K)
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 12,142 Common Stock at $212.27 (~$2.58M)
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 5,034 Common Stock at $213.43 (~$1.07M)
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 5,707 Common Stock at $214.35 (~$1.22M)
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 3,161 Common Stock at $215.38 (~$681K)
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 7,182 Common Stock at $216.51 (~$1.55M)
16-06-2026
Chief Legal Officer & EVP Pentland Adele Louise had withheld for taxes 3,676 Common Stock at $206.36 (~$759K). Pentland Adele Louise holds 5,323.759 shares after the transaction.
- · Chief Legal Officer & EVP Pentland Adele Louise exercised/converted 7,800 Common Stock
- · Chief Legal Officer & EVP Pentland Adele Louise had withheld for taxes 3,676 Common Stock at $206.36 (~$759K)
- · Chief Legal Officer & EVP Pentland Adele Louise exercised/converted 7,800 Restricted Stock Units
16-06-2026
Chief Legal Officer, Secretary Reilly John Charles sold 54,244 Common Stock at $5.21 (~$283K). Reilly John Charles holds 1,057,975 shares after the transaction.
- · Chief Legal Officer, Secretary Reilly John Charles had withheld for taxes 17,574 Common Stock at $5.23 (~$91.9K)
- · Chief Legal Officer, Secretary Reilly John Charles sold 900 Common Stock at $5.22 (~$4.7K)
- · Chief Legal Officer, Secretary Reilly John Charles sold 54,244 Common Stock at $5.21 (~$283K)
16-06-2026
Chief Executive Officer Cohen Jon R had withheld for taxes 99,720 Common Stock at $5.23 (~$522K). Cohen Jon R holds 2,851,880 shares after the transaction.
- · Chief Executive Officer Cohen Jon R had withheld for taxes 99,720 Common Stock at $5.23 (~$522K)
16-06-2026
Chief Marketing Officer Watson Katelyn had withheld for taxes 7,181 Common Stock at $5.23 (~$37.6K). Watson Katelyn holds 390,222 shares after the transaction.
- · Chief Marketing Officer Watson Katelyn had withheld for taxes 7,181 Common Stock at $5.23 (~$37.6K)
16-06-2026
Director Hooper Christopher gifted 30,000 Class A Common Stock. Hooper Christopher holds 105,260 shares after the transaction.
- · Director Hooper Christopher gifted 30,000 Class A Common Stock
16-06-2026
Chief Financial Officer Harris Ian Jiro had withheld for taxes 38,561 Common Stock at $5.23 (~$202K). Harris Ian Jiro holds 741,112 shares after the transaction.
- · Chief Financial Officer Harris Ian Jiro had withheld for taxes 38,561 Common Stock at $5.23 (~$202K)
16-06-2026
Director Smaldone Alsup Laurie was awarded 6,009 Ordinary Shares. Smaldone Alsup Laurie holds 80,989 shares after the transaction.
- · Director Smaldone Alsup Laurie was awarded 6,009 Ordinary Shares
- · Director Smaldone Alsup Laurie was awarded 13,398 Share Option (Right to Buy)
16-06-2026
Chief Executive Officer Condor Theresa had withheld for taxes 14,423 Class A Common Stock at $18.23 (~$263K). 9 transactions reported in total. Condor Theresa holds 971,188 shares after the transaction.
- · Chief Executive Officer Condor Theresa exercised/converted 2,285 Class A Common Stock at $7.04 (~$16.1K)
- · Chief Executive Officer Condor Theresa exercised/converted 18,282 Class A Common Stock at $7.04 (~$129K)
- · Chief Executive Officer Condor Theresa exercised/converted 554 Class A Common Stock at $7.84 (~$4.34K)
- · Chief Executive Officer Condor Theresa exercised/converted 820 Class A Common Stock at $7.84 (~$6.43K)
- · Chief Executive Officer Condor Theresa had withheld for taxes 14,423 Class A Common Stock at $18.23 (~$263K)
- · Chief Executive Officer Condor Theresa exercised/converted 2,285 Stock Option (right to buy)
- · Chief Executive Officer Condor Theresa exercised/converted 18,282 Stock Option (right to buy)
- · Chief Executive Officer Condor Theresa exercised/converted 554 Stock Option (right to buy)
16-06-2026
Director Messer Stephen disposed of 24,660 Class A Common Stock. Messer Stephen holds 101,653 shares after the transaction.
- · Director Messer Stephen disposed of 24,660 Class A Common Stock
- · Director Messer Stephen acquired 12,330 Class A Common Stock
- · Director Messer Stephen was awarded 7,261 Class A Common Stock
17-06-2026
17 Education & Technology Group Inc. reported its unaudited first quarter 2026 financial results via a press release furnished as an exhibit to this Form 6-K filing. The filing covers results for the quarter ended March 31, 2026.
- · The filing was made on June 17, 2026.
- · The press release (Exhibit 99.1) contains unaudited financial results for the first quarter of 2026.
- · The company is a foreign private issuer filing under Form 6-K.
- · The principal executive office is located in Beijing, China.
17-06-2026
This 20-F filing is an annual report detailing Takeda's extensive pipeline across multiple therapeutic areas. The report highlights several recent regulatory milestones including approvals and filings for key assets such as ADZYNMA (congenital TTP) in China, VONVENDI/VEYVONDI (von Willebrand disease) in Japan, EU, and the U.S., and multiple immunoglobulin products (TAK-961, TAK-339, TAK-771, TAK-880) in Japan and elsewhere. However, the pipeline also shows many assets in early-to-mid-stage trials (Phase I/II) and some programs in earlier development without concrete near-term catalysts, highlighting the balanced risk profile of a large pharma pipeline.
- · TAK-279 (zasocitinib) is in Phase III for psoriasis globally and also in Phase III for pediatric psoriasis, Phase III for psoriatic arthritis, but only Phase IIb for Crohn's disease, ulcerative colitis, and vitiligo, and Phase IIa for hidradenitis suppurativa.
- · TAK-079 (mezagitamab) is in Phase III for immune thrombocytopenia and IgA nephropathy globally.
- · TAK-227/ZED1227 is only in Phase IIb for celiac disease.
- · TAK-101 is only in Phase II for celiac disease.
- · TAK-781 is in Phase I for primary sclerosing cholangitis.
- · TAK-755 is only in Phase II for acute ischemic stroke.
- · TAK-360 is in Phase II for idiopathic hypersomnia and narcolepsy type 2.
- · TAK-495 is in Phase I and has disclosed no specific indication.
- · TAK-853 is filed in Japan for platinum-resistant ovarian cancer but only in Phase III for platinum-sensitive ovarian cancer.
- · TAK-226 is in Phase III globally for 2L MDS anemia but only in Phase II for anemia-associated myelofibrosis.
- · TAK-928/IBI363 is in Phase III for 2L squamous NSCLC but only in Phase II for solid tumors.
- · TAK-921/IBI343 is in Phase III for 3L gastric cancer in Japan and China but only in Phase I for solid tumors.
- · TAK-168/KQB168 and TAK-188 are both in Phase I for solid tumors.
- · TAK-330 is in Phase III in the U.S. for DOAC reversal in surgical settings.
- · TAK-881 is in Phase III for primary immunodeficiencies and CIDP across U.S., EU, and Japan.
- · TAK-411 is only in Phase II for CIDP.
- · HQP1351 is in Phase III for CML in U.S., EU, and Japan.
- · ACI-24.060 is in Phase II for Alzheimer's disease.
- · IBI3001 is in Phase I for solid tumors.
17-06-2026
Aegon Ltd. announced leadership changes and selected New York City as the location for its future corporate headquarters, ahead of its planned redomiciliation from Bermuda to the United States. Will Fuller will be appointed President and COO effective January 1, 2027, and CEO Lard Friese will relocate to the U.S. in early 2027. No financial metrics were disclosed; the announcement is purely strategic and organizational.
- · Will Fuller will become President and COO effective January 1, 2027, reporting to CEO Lard Friese.
- · Lard Friese will relocate to the United States at the beginning of 2027.
- · New York City headquarters office expected to open in mid-2027.
- · An extraordinary general meeting of shareholders is contemplated in Q4 2026 to approve the redomiciliation.
- · Aegon is currently domiciled in Bermuda, headquartered in Schiphol, Netherlands, and listed on Euronext Amsterdam and NYSE.
17-06-2026
POMDOCTOR LIMITED announced that its ADS ratio change will become effective on June 22, 2026, converting the current ratio of 1 ADS representing 1/6 Class A ordinary share to 1 ADS representing 3 Class A ordinary shares. This change effectively acts as a one-for-eighteen reverse ADS split, with no change to the underlying Class A ordinary shares. The Company expects the ADS trading price to increase proportionally, but cautions that it cannot guarantee the post-change price will be equal to or greater than eighteen times the pre-change price.
- · The ADS Ratio Change will be effective on June 22, 2026, U.S. Eastern Time.
- · The new CUSIP number for the ADSs will be 73181R207.
- · No fractional new ADSs will be issued; fractional entitlements will be sold and net cash proceeds distributed to holders.
- · The Company ranks sixth on China’s Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan.
17-06-2026
NeoGenomics, Inc. announced the pricing of an offering of convertible senior notes due 2032 to qualified institutional buyers on June 17, 2026. The filing does not disclose the size, interest rate, or conversion terms of the offering, nor does it provide any financial results or operational updates.
- · The offering is made only to qualified institutional buyers under Rule 144A.
- · The notes are due in 2032.
- · The press release detailing the pricing is filed as Exhibit 99.1.
17-06-2026
Alterity Therapeutics Ltd filed a Form 6-K with the SEC on June 17, 2026, reporting changes in director's interests. The filing includes two Change of Director's Interest Notices as exhibits. No financial results or material operational updates were disclosed.
- · The filing incorporates by reference into several existing SEC registration statements (Forms S-8 and F-3).
- · Exhibits include two Change of Director's Interest Notices (Exhibit 99.1).
17-06-2026
Magnum Ice Cream Co N.V. filed a Form 6-K on June 17, 2026, disclosing the grant of stock options to six key executives on June 16, 2026. The options were granted at exercise prices of €15.33 (EUR) and £13.23 (GBP), with the largest grants going to CFO Abhijit Bhattacharya (1,330,010 options, total €20.4M) and CHRO Ronald Schellekens (1,071,235 options, total £14.2M). The filing is a routine PDMR notification and does not contain any financial results or performance data.
- · All transactions occurred on June 16, 2026, outside a trading venue.
- · The options are for ordinary shares of €3.50 each, ISIN NL0015002MS2.
- · The grant to CFO Abhijit Bhattacharya is the largest by both volume (1,330,010 options) and total value (€20,389,053.30).
- · The grant to CHRO Ronald Schellekens is the second largest by volume (1,071,235 options) and total value (£14,172,439.05).
- · The smallest grant was to Victoria McKenzie-Gould (48,212 options, €739,089.96).
17-06-2026
Aegon Ltd. announces leadership changes and selects New York City as the location for its future corporate headquarters as part of its planned redomiciliation to the United States. Will Fuller will be appointed President and Chief Operating Officer (COO) effective January 1, 2027, reporting to CEO Lard Friese, who will relocate to the U.S. in early 2027. The move is aimed at sharpening execution and accelerating performance improvement, but no financial metrics or current performance data are provided in the filing.
- · Will Fuller's appointment as President and COO is effective January 1, 2027.
- · Will Fuller has been President and CEO of Transamerica since March 2021 and previously held senior roles at Lincoln Financial Group and Merrill Lynch.
- · The New York City corporate headquarters is expected to open in mid-2027.
- · The redomiciliation is subject to regulatory approvals and shareholder vote, with an extraordinary general meeting contemplated in Q4 2026.
- · Aegon's portfolio includes fully owned businesses in the U.S. and U.K., a global asset manager, and insurance joint ventures in Spain & Portugal, China, and Brazil.
- · Aegon is currently headquartered in Schiphol, Netherlands, domiciled in Bermuda, and listed on Euronext Amsterdam and the NYSE.
17-06-2026
This 6-K filing reports the results of shareholder votes on two agenda items at Korea Electric Power Corp, with overwhelming approval of 97.4% on Item 1 (both sub-items) and 99.1% / 98.8% on Item 2 sub-items. No specific financial performance or business updates are included.
- · Item 1 was voted on two sub-items: 1-1 and 1-2, each with the same outstanding share count (641,964,077) and attendant shares (437,575,526).
- · Item 2 sub-items had smaller share counts: 326,879,901 outstanding and 122,491,350 attendant shares.
- · Approval percentages were uniformly high, ranging from 97.4% to 99.1%.
- · The filing does not disclose the specific topics of the agenda items or any financial figures.
17-06-2026
JBDI Holdings Ltd (Nasdaq: JBDI) received a Nasdaq determination letter on January 7, 2026, for non-compliance with the minimum bid price rule (closing below $1 per share for 30 consecutive business days). To regain compliance by the July 6, 2026 deadline, the company announced a 1-for-2 reverse stock split effective June 25, 2026. If compliance is not achieved and an additional grace period is not granted, the company's shares may be delisted.
- · The reverse stock split is expected to be effective on or about June 25, 2026, with a record date of June 25, 2026.
- · Trading on a split-adjusted basis under the ticker 'JBDI' is expected to begin on the trading day following the effective date.
- · If the company fails to regain compliance by July 6, 2026, and is ineligible for an additional grace period, Nasdaq will issue a delisting notice; the company may appeal to a hearings panel.
17-06-2026
Wing Yip Food Holdings Group Ltd (Nasdaq: WYHG) announced on June 16, 2026 that it regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)). The company's ADS closing bid price had been below $1.00 for 30 consecutive business days as of December 22, 2025, but subsequently closed at or above $1.00 for 10 consecutive business days from June 2 to June 15, 2026, resolving the deficiency.
- · Wing Yip's ordinary shares have been listed on the Korea Securities Dealers Automated Quotations (KOSDAQ) of the Korea Exchange since 2018.
- · The company sells products through self-operated stores, distributors, and e-commerce platforms in over 18 provinces across mainland China.
- · The Wing Yip brand traces its history back to 1915.
17-06-2026
Organon & Co. is soliciting stockholder approval for its acquisition by Sun Pharmaceutical Industries Ltd. via a merger with Sun Pharma USA's subsidiary, with stockholders to vote on the Merger Agreement Proposal and a non-binding advisory Compensation Proposal at a Special Meeting on July 23, 2026. The Board unanimously recommends voting FOR both proposals, and the merger consideration is based on the terms of the Merger Agreement dated April 26, 2026. Stockholders who fail to vote or abstain will effectively count as votes against the Merger Agreement Proposal, which requires approval by a majority of outstanding shares.
- · The Special Meeting will be held virtually on July 23, 2026 at 10:00 a.m. Eastern Time.
- · Record date for voting is June 15, 2026.
- · Approval of the Merger Agreement Proposal requires the affirmative vote of holders of a majority of outstanding shares of Organon common stock entitled to vote.
- · The Merger Agreement was dated April 26, 2026.
- · Organon was formed through a spinoff from Merck & Co., Inc. in 2021.
- · Organon's principal executive offices are at 30 Hudson Street, Floor 33, Jersey City, New Jersey 07302.
- · Sun Pharma USA's principal executive offices are at 2 Independence Way, Princeton, NJ 08540.
- · Merger Sub has not engaged in any business or operations except activities incidental to its formation and the merger.
17-06-2026
Holcim Ltd. and its affiliate Inversiones ASPI S.A. filed an amended Schedule 13D disclosing beneficial ownership of 211,985,547 common shares (50.01%) of Cementos Pacasmayo SAA as of June 16, 2026. On June 15, 2026, Holcim's Executive Committee determined to proceed with a public tender offer for any and all outstanding common shares, indicating a potential full acquisition.
- · The filing is an amendment to the original Schedule 13D filed on April 4, 2026.
- · The public tender offer will be for any and all issued and outstanding common shares.
- · The ownership percentage is based on 423,868,449 common shares outstanding as of June 16, 2026.
17-06-2026
Toyota Motor Corporation's filing details its governance structure, strategic equity investments, and executive compensation framework. The company holds significant stakes in partners such as NTT, MS&AD Insurance, and MUFG for smart city, mobility AI, and financial service collaborations, while recently selling a portion of its MS&AD and MUFG holdings. Toyota's compensation metrics show strong performance on operating income (STI at 134% of a ¥2.5 trillion reference value) but ROE evaluation is benchmarked at only 8%, indicating room for improved capital efficiency.
- · Toyota's board determined Hiromi Osada independent despite her past executive role at Chunichi Shimbun, citing immaterial business transactions (<0.2% of consolidated sales in last 3 years).
- · Ownership in Bridgestone Corporation increased due to a return from retirement benefit trust.
- · Positions in Grab, Pony AI, Uber, Aurora, Inchcape, and Yamato are held with 'No' voting rights limitations.
- · LTI uses a 5-year total shareholder return comparison against TOPIX (reference: 202.2%) and ROE benchmark of 8%.
Get daily alerts with 12 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Pre-Market SEC Filings Roundup
🇺🇸 More from United States
View all →June 09, 2026
US SEC Trading Suspension Halt Orders — June 09, 2026
US SEC Trading Suspension Halt Orders
June 09, 2026
US Earnings Financial Results SEC Filings — June 09, 2026
US Earnings Financial Results SEC Filings
June 09, 2026
Global High-Priority Regulatory Events — June 09, 2026
Global High-Priority Regulatory Events
June 09, 2026
S&P 500 Technology Sector SEC Filings — June 09, 2026
S&P 500 Technology Sector SEC Filings